Get the Stockscreener App
134.74
0.14%
0.17
Apogee Therapeutics Inc stock is traded at $134.74, with a volume of 722.57K.
It is up +0.14% in the last 24 hours and up +0.56% over the past month.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$134.57
Open:
$134.83
24h Volume:
722.57K
Relative Volume:
0.28
Market Cap:
$10.20B
Revenue:
-
Net Income/Loss:
$-274.62M
P/E Ratio:
-31.13
EPS:
-4.3278
Net Cash Flow:
$-235.37M
1W Performance:
+0.15%
1M Performance:
+0.56%
6M Performance:
+95.50%
1Y Performance:
+270.10%
1-Day Range:
$134.74
$134.88
1-Week Range:
$134.40
$134.88
52-Week Range:
$35.39
$134.88
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
134.74 | 10.19B | 0 | -274.62M | -235.37M | -4.3278 |
VRTX
Vertex Pharmaceuticals Inc
|
544.07 | 130.67B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
837.88 | 82.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,024.85 | 61.80B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
144.62 | 25.73B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
216.00 | 45.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Hold |
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighShould You Buy? - MarketBeat
AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition - Kalkine Media
AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition - Investing.com
NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal - TradingView
What Will Apogee Therapeutics (NASDAQ:APGE) Say on Trials? - Kalkine Media
Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO Dambkowski sells $737k in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics CMO Dambkowski sells $737k in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Liquidity Mapping Around (APGE) Price Events - Stock Traders Daily
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE - MarketBeat
This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Truist Financial Maintains Apogee Therapeutics(APGE.US) With Hold Rating, Raises Target Price to $135 - Moomoo
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History - Yahoo Finance
Apogee Therapeutics Director Vote: My Take On The 8-K Liga Mx (YjhKcvC1lD) - Mshale
Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research - MarketBeat
APGE Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
BTIG Downgrades Apogee Therapeutics to Neutral From Buy - marketscreener.com
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal By Investing.com - Investing.com South Africa
BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal - Investing.com Nigeria
APOGEE THERAPEUTICS, INC. : BTIG CUTS TO NEUTRAL FROM BUY - Bitget
Apogee Therapeutics Directors Execute Stock Options, Increasing Holdings - Kalkine Media
Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options - Stock Titan
Apogee Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com
Apogee Therapeutics,Q2 2026 Net Loss $85.9 - Moomoo
My Takeaway On Apogee Therapeutics' Massive Cash Raise Humberto Cruz (GVA0ZiS739) - Mshale
Apogee Therapeutics, Inc. (APGE): An Insightful Stock Analysis on Growth Potential and Market Position - DirectorsTalk Interviews
APGE SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Apogee Therapeutics Reports Q2 2026 Results and Announces Merger Agreement with AbbVie Subsidiary - Kalkine Media
Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary - TradingView
Apogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS - MarketBeat
Apogee Therapeutics Q2 Loss Widens - marketscreener.com
Earnings Flash (APGE) Apogee Therapeutics Posts Q2 Net Loss $85.9M, vs. FactSet Est of $78.7M Loss - marketscreener.com
Apogee reports $85.9 million Q2 loss as AbbVie deal advances - Quiver Quantitative
Apogee Therapeutics reports Q2 2026 results; cash and marketable securities $1.3B, net loss $85.9M - TradingView
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates - The Manila Times
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion; Apogee Reports Positive Phase 2 Zumilokibart Data and Q2 2026 Results - Quiver Quantitative
Apogee's Atopic Dermatitis Drug Shows 65.9% EASI-75 - Stock Titan
Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE - MarketBeat
Apogee Therapeutics (APGE) Earnings Date and Reports 2026 $APGE - marketbeat.com
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares By Investing.com - Investing.com India
Apogee Therapeutics CMO Carl Dambkowski disposes of USD 737,935 in common shares - Bitget
Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan - Stock Titan
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics stock hits all-time high at 134.47 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock hits all-time high at 134.47 USD - Investing.com
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):